ERBB2 and breast cancer: Similarly, a six-RNA model comprising lnc-MCL1-2, Val-AAC-5-1-tRF5D, RNU2-14P, piR-32971, SNORA36C, and LINC00567[−]/ING1-1[+] could distinguish between BC patients with HER2+ and HER2− tumors with an AUC of 0.976 (95% CI = 0.937–1.015, p = 4.8 × 10−6) on the training set and an AUC of 0.929 (95% CI = 0.8233–1.034, p = 3.2 × 10−5) in the LOOCV (Figure 5e,f).